JP2019513817A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513817A5 JP2019513817A5 JP2018566191A JP2018566191A JP2019513817A5 JP 2019513817 A5 JP2019513817 A5 JP 2019513817A5 JP 2018566191 A JP2018566191 A JP 2018566191A JP 2018566191 A JP2018566191 A JP 2018566191A JP 2019513817 A5 JP2019513817 A5 JP 2019513817A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- chain variable
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022104519A JP2022126847A (ja) | 2016-03-04 | 2022-06-29 | Ｔｉｇｉｔに対する抗体 |
| JP2024218931A JP2025032326A (ja) | 2016-03-04 | 2024-12-13 | Ｔｉｇｉｔに対する抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662304045P | 2016-03-04 | 2016-03-04 | |
| US62/304,045 | 2016-03-04 | ||
| US201662413025P | 2016-10-26 | 2016-10-26 | |
| US62/413,025 | 2016-10-26 | ||
| PCT/US2017/020719 WO2017152088A1 (en) | 2016-03-04 | 2017-03-03 | Antibodies to tigit |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104519A Division JP2022126847A (ja) | 2016-03-04 | 2022-06-29 | Ｔｉｇｉｔに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513817A JP2019513817A (ja) | 2019-05-30 |
| JP2019513817A5 true JP2019513817A5 (https=) | 2020-04-16 |
| JP7109382B2 JP7109382B2 (ja) | 2022-07-29 |
Family
ID=59744453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566191A Active JP7109382B2 (ja) | 2016-03-04 | 2017-03-03 | Ｔｉｇｉｔに対する抗体 |
| JP2022104519A Withdrawn JP2022126847A (ja) | 2016-03-04 | 2022-06-29 | Ｔｉｇｉｔに対する抗体 |
| JP2024218931A Pending JP2025032326A (ja) | 2016-03-04 | 2024-12-13 | Ｔｉｇｉｔに対する抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022104519A Withdrawn JP2022126847A (ja) | 2016-03-04 | 2022-06-29 | Ｔｉｇｉｔに対する抗体 |
| JP2024218931A Pending JP2025032326A (ja) | 2016-03-04 | 2024-12-13 | Ｔｉｇｉｔに対する抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10537633B2 (https=) |
| EP (1) | EP3423089A4 (https=) |
| JP (3) | JP7109382B2 (https=) |
| KR (2) | KR102355950B1 (https=) |
| CN (2) | CN116514976A (https=) |
| AU (2) | AU2017228474C1 (https=) |
| CA (1) | CA3014934A1 (https=) |
| IL (1) | IL261188B (https=) |
| MX (1) | MX2018010485A (https=) |
| MY (2) | MY202516A (https=) |
| PH (1) | PH12018501778A1 (https=) |
| SA (2) | SA522431756B1 (https=) |
| SG (1) | SG11201806992VA (https=) |
| TW (3) | TWI805127B (https=) |
| UA (1) | UA125898C2 (https=) |
| UY (1) | UY37141A (https=) |
| WO (1) | WO2017152088A1 (https=) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2860170C (en) | 2010-12-22 | 2022-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN105722860A (zh) | 2013-09-24 | 2016-06-29 | 梅迪塞纳医疗股份有限公司 | 白介素-2融合蛋白及其应用 |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US10537633B2 (en) * | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| JP7066696B2 (ja) | 2016-10-11 | 2022-05-13 | アジェナス インコーポレイテッド | 抗ｌａｇ－３抗体及びその使用方法 |
| MX2019006072A (es) | 2016-11-30 | 2019-08-14 | Oncomed Pharm Inc | Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit). |
| US20200024351A1 (en) | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
| JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
| WO2018229163A1 (en) * | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| IL272227B2 (en) | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| WO2019023504A1 (en) | 2017-07-27 | 2019-01-31 | Iteos Therapeutics Sa | ANTI-TIGIT ANTIBODIES |
| JP7317272B2 (ja) * | 2017-09-29 | 2023-07-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 |
| CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
| WO2019173692A2 (en) | 2018-03-09 | 2019-09-12 | Agenus Inc. | Anti-cd73 antibodies and methods of use thereof |
| AU2019239850A1 (en) * | 2018-03-19 | 2020-10-29 | Lanier Biotherapeutics, Inc. | High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (PD-L1) and uses thereof |
| KR20210016448A (ko) | 2018-06-01 | 2021-02-15 | 컴퓨젠 엘티디. | 항-pvrig/항-tigit 이중특이적 항체 및 사용 방법 |
| WO2020020281A1 (zh) | 2018-07-25 | 2020-01-30 | 信达生物制药(苏州)有限公司 | 抗tigit抗体及其用途 |
| JP2021534196A (ja) | 2018-08-23 | 2021-12-09 | シージェン インコーポレイテッド | 抗ｔｉｇｉｔ抗体 |
| JP7575100B2 (ja) * | 2018-11-13 | 2024-10-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫細胞活性化のための二重特異性抗体 |
| KR20210108978A (ko) | 2018-12-21 | 2021-09-03 | 오제 이뮈노테라프틱스 | 이작용성 항-pd-1/il-7 분자 |
| US12312401B2 (en) | 2019-01-07 | 2025-05-27 | Iteos Belguim Sa | Anti-TIGIT antibodies |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2020185739A1 (en) | 2019-03-11 | 2020-09-17 | Jounce Therapeutics, Inc. | Anti-icos antibodies for the treatment of cancer |
| CN109734806B (zh) * | 2019-03-15 | 2022-07-01 | 安徽安科生物工程（集团）股份有限公司 | 一种全人源抗huTIGIT单克隆抗体及其应用 |
| KR102332847B1 (ko) * | 2019-06-13 | 2021-12-01 | 주식회사 녹십자 | Tigit에 대한 항체 및 이의 용도 |
| CA3146986A1 (en) * | 2019-07-15 | 2021-01-21 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibodies and application thereof |
| MX2022003195A (es) | 2019-09-18 | 2022-04-11 | Molecular Templates Inc | Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. |
| WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
| JP2022548978A (ja) * | 2019-09-27 | 2022-11-22 | ジェネンテック， インコーポレイテッド | 薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬 |
| JP2022554270A (ja) | 2019-11-05 | 2022-12-28 | ジョンス セラピューティクス， インコーポレイテッド | 抗ｐｄ－１抗体による癌を治療する方法 |
| WO2021093849A1 (en) * | 2019-11-14 | 2021-05-20 | Wuxi Biologics (Shanghai) Co., Ltd. | A novel antibody against tigit |
| US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CN115943312A (zh) | 2020-05-07 | 2023-04-07 | 法国居里学院 | 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途 |
| CN111995681B (zh) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| MX2022015157A (es) | 2020-06-02 | 2023-01-16 | Arcus Biosciences Inc | Anticuerpos para tigit. |
| KR20230024368A (ko) | 2020-06-18 | 2023-02-20 | 제넨테크, 인크. | 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료 |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US20240002504A1 (en) * | 2020-10-26 | 2024-01-04 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| WO2022105872A1 (zh) * | 2020-11-23 | 2022-05-27 | 广东菲鹏制药股份有限公司 | 抗tigit抗体或其抗原结合片段 |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| KR102788520B1 (ko) * | 2020-11-25 | 2025-04-01 | 주식회사 와이바이오로직스 | Tigit에 특이적으로 결합하는 항체 및 그의 용도 |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022124864A1 (ko) * | 2020-12-10 | 2022-06-16 | 주식회사 유틸렉스 | 항-tigit 항체 및 이의 용도 |
| EP4262858A1 (en) | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| MX2023013335A (es) | 2021-05-10 | 2024-01-16 | Medimabbio Inc | Anticuerpos anti-tigit y usos de los mismos. |
| WO2023010094A2 (en) | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
| WO2023020625A1 (zh) * | 2021-08-20 | 2023-02-23 | 中山康方生物医药有限公司 | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
| CN114480298B (zh) * | 2022-04-14 | 2022-06-24 | 迈杰转化医学研究(苏州)有限公司 | 一株分泌抗tigit单克隆抗体的杂交瘤细胞株及其应用 |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2023234748A1 (ko) * | 2022-06-03 | 2023-12-07 | 메디맵바이오 주식회사 | 항-tigit 항체 및 이의 용도 |
| KR20250022049A (ko) | 2022-06-07 | 2025-02-14 | 제넨테크, 인크. | 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법 |
| KR102769148B1 (ko) * | 2022-06-10 | 2025-02-20 | 메디맵바이오 주식회사 | 항-tigit 항체, 인터류킨-15, 및 인터류킨-15 수용체 알파 스시 도메인을 포함하는 융합 단백질 및 이의 용도 |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| CN120202220A (zh) * | 2022-08-26 | 2025-06-24 | 南京传奇生物科技有限公司 | 靶向tigit的抗体及其用途 |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4687991A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024211551A1 (en) | 2023-04-06 | 2024-10-10 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024249894A2 (en) | 2023-06-02 | 2024-12-05 | Arcus Biosciences, Inc. | Biomarkers for predicting cancer treatment efficacy |
| TW202515608A (zh) | 2023-06-26 | 2025-04-16 | 以色列商坎布根有限公司 | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 |
| WO2025002151A1 (zh) * | 2023-06-27 | 2025-01-02 | 正大天晴药业集团股份有限公司 | 抗tigit抗体及其应用 |
| WO2025038857A1 (en) | 2023-08-16 | 2025-02-20 | Arcus Biosciences, Inc. | TETRALINS TARGETING MUTANT HIF-2α |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| WO2025137370A1 (en) | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
| WO2025235493A1 (en) | 2024-05-07 | 2025-11-13 | Arcus Biosciences, Inc. | Casdatifan for use in the treatment of cancer |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026059973A1 (en) | 2024-09-11 | 2026-03-19 | Arcus Biosciences, Inc. | Biomarkers for methods of treating cancer |
| WO2026059987A1 (en) | 2024-09-11 | 2026-03-19 | Arcus Biosciences, Inc. | Biomarkers for methods of treating cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| ES2155854T3 (es) | 1993-06-09 | 2001-06-01 | Unilever Nv | Procedimiento de produccion de proteinas de fusion que comprende fragmentos de scfv con la ayuda de un molde transformado. |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| US7473423B2 (en) | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| AU2937597A (en) | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| NZ513144A (en) | 1999-02-05 | 2003-05-30 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
| WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS OF TREATING IMMUNE-INFLAMMATORY DISEASES |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック， インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
| AU2004229501B2 (en) * | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| JP5004154B2 (ja) | 2005-04-06 | 2012-08-22 | 一般財団法人化学及血清療法研究所 | 組換え抗ボツリヌス神経毒素抗体 |
| EP1891107B1 (en) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| WO2007124283A2 (en) | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
| CA2676843A1 (en) | 2007-01-29 | 2008-08-07 | Valtion Teknillinen Tutkimuskeskus | Method for producing novel ige based reagents |
| FI20075059A0 (fi) | 2007-01-29 | 2007-01-29 | Valtion Teknillinen | Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus |
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| EP2220247A4 (en) | 2007-11-16 | 2011-10-26 | Nuvelo Inc | ANTIBODY AGAINST LRP6 |
| WO2009073163A1 (en) | 2007-12-03 | 2009-06-11 | American Type Culture Collection (Atcc) | Avian influenza antibodies, compositions, and methods thereof |
| SG10202112838YA (en) * | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| WO2009154026A1 (ja) | 2008-06-20 | 2009-12-23 | 国立大学法人岡山大学 | 石灰化小球に対する抗体及びその用途 |
| FR2933702A1 (fr) * | 2008-07-08 | 2010-01-15 | Sanofi Aventis | Antagonistes specifiques du recepteur fgf-r4 |
| US8183346B2 (en) | 2008-12-05 | 2012-05-22 | Eli Lilly And Company | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
| CN102459335B (zh) | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| WO2011016238A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| FR2959416B1 (fr) | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| US8822642B2 (en) | 2010-06-09 | 2014-09-02 | Zymogenetics, Inc. | Dimeric fusion proteins and related compositions and methods |
| JP2012021943A (ja) | 2010-07-16 | 2012-02-02 | National Cancer Center | 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体 |
| KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| US8962804B2 (en) | 2010-10-08 | 2015-02-24 | City Of Hope | Meditopes and meditope-binding antibodies and uses thereof |
| EA201390472A1 (ru) | 2010-10-29 | 2014-02-28 | Иммьюноджен, Инк. | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты |
| WO2012078793A2 (en) | 2010-12-07 | 2012-06-14 | Board Of Regents, The University Of Texas System | Methods and compositions related to tazarotene-induced gene 1 (tig1) |
| NZ611428A (en) | 2010-12-08 | 2015-07-31 | Stemcentrx Inc | Novel modulators and methods of use |
| TW201247706A (en) | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| US20120244155A1 (en) | 2011-03-22 | 2012-09-27 | Baylor Research Institute | Dendritic Cells (DCs) Targeting for Tuberculosis (TB) Vaccine |
| CA2831294A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
| JPWO2012176765A1 (ja) | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| WO2013125654A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| ES2739612T3 (es) | 2012-02-21 | 2020-02-03 | Toray Industries | Composición farmacéutica para el tratamiento de cáncer |
| EP3539985A1 (en) | 2012-02-24 | 2019-09-18 | AbbVie Stemcentrx LLC | Anti sez6 antibodies and methods of use |
| JP6107654B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び／又は予防用医薬組成物 |
| WO2013147176A1 (ja) | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び／又は予防用医薬組成物 |
| US9243070B2 (en) | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor Bb antibodies and uses thereof |
| CA2869704A1 (en) | 2012-04-04 | 2013-10-10 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (pcadherin) antibody |
| MX2014013806A (es) | 2012-05-14 | 2014-11-26 | Genentech Inc | Composiciones y metodos para el diagnostico y tratamiento de tumores. |
| EP3202419A1 (en) | 2012-06-06 | 2017-08-09 | OncoMed Pharmaceuticals, Inc. | Pvrig binding agents that modulate the hippo pathway and uses thereof |
| EP3508215A3 (en) | 2012-12-03 | 2019-10-02 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
| HK1210964A1 (en) | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| EP3594240B1 (en) | 2013-05-20 | 2023-12-06 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| US10364288B2 (en) | 2013-05-24 | 2019-07-30 | Biogen Ma Inc. | Anti-GPIIB/IIIA antibodies or uses thereof |
| TW201536811A (zh) | 2013-05-31 | 2015-10-01 | Biogen Idec Inc | 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途 |
| BR112016000853A2 (pt) | 2013-07-16 | 2017-12-12 | Genentech Inc | métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit |
| JP2015066079A (ja) | 2013-09-27 | 2015-04-13 | オリンパス株式会社 | 超音波処置具、及び手術システム |
| IL263466B2 (en) | 2013-12-17 | 2023-10-01 | Genentech Inc | Anti-CD3 antibodies and methods of using them |
| AU2014370404A1 (en) | 2013-12-24 | 2016-07-07 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| WO2015133882A1 (ko) | 2014-03-07 | 2015-09-11 | 사회복지법인 삼성생명공익재단 | ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법 |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| KR20160146747A (ko) | 2014-03-31 | 2016-12-21 | 제넨테크, 인크. | 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법 |
| EP3169363A4 (en) * | 2014-07-16 | 2018-02-21 | F. Hoffmann-La Roche AG | Methods of treating cancer using tigit inhibitors and anti-cancer agents |
| WO2016022883A1 (en) | 2014-08-07 | 2016-02-11 | Memorial Sloan-Kettering Cancer Center | Anti-ceramide antibodies |
| MD4733C1 (ro) * | 2014-08-19 | 2021-07-31 | Merck Sharp & Dohme Corp | Anticorpi anti-TIGIT |
| US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
| US10508151B2 (en) | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| WO2016081640A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| JP6180663B2 (ja) | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| US10537633B2 (en) * | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
-
2017
- 2017-03-03 US US15/449,665 patent/US10537633B2/en active Active
- 2017-03-03 TW TW110147016A patent/TWI805127B/zh active
- 2017-03-03 SG SG11201806992VA patent/SG11201806992VA/en unknown
- 2017-03-03 UY UY0001037141A patent/UY37141A/es active IP Right Grant
- 2017-03-03 EP EP17760920.3A patent/EP3423089A4/en active Pending
- 2017-03-03 JP JP2018566191A patent/JP7109382B2/ja active Active
- 2017-03-03 MX MX2018010485A patent/MX2018010485A/es unknown
- 2017-03-03 KR KR1020187028576A patent/KR102355950B1/ko active Active
- 2017-03-03 MY MYPI2021004070A patent/MY202516A/en unknown
- 2017-03-03 TW TW112118186A patent/TW202409084A/zh unknown
- 2017-03-03 WO PCT/US2017/020719 patent/WO2017152088A1/en not_active Ceased
- 2017-03-03 MY MYPI2018702878A patent/MY191649A/en unknown
- 2017-03-03 UA UAA201809862A patent/UA125898C2/uk unknown
- 2017-03-03 AU AU2017228474A patent/AU2017228474C1/en active Active
- 2017-03-03 CN CN202310300367.4A patent/CN116514976A/zh active Pending
- 2017-03-03 CA CA3014934A patent/CA3014934A1/en active Pending
- 2017-03-03 IL IL261188A patent/IL261188B/en unknown
- 2017-03-03 TW TW106107115A patent/TWI752012B/zh active
- 2017-03-03 KR KR1020227002189A patent/KR102588359B1/ko active Active
- 2017-03-03 CN CN201780015226.0A patent/CN108883164B/zh active Active
-
2018
- 2018-08-22 PH PH12018501778A patent/PH12018501778A1/en unknown
- 2018-09-02 SA SA522431756A patent/SA522431756B1/ar unknown
- 2018-09-02 SA SA518392332A patent/SA518392332B1/ar unknown
-
2019
- 2019-12-04 US US16/703,770 patent/US11723971B2/en active Active
-
2022
- 2022-06-29 JP JP2022104519A patent/JP2022126847A/ja not_active Withdrawn
-
2023
- 2023-06-21 US US18/338,847 patent/US20240115696A1/en active Pending
-
2024
- 2024-01-02 AU AU2024200018A patent/AU2024200018A1/en active Pending
- 2024-12-13 JP JP2024218931A patent/JP2025032326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019513817A5 (https=) | ||
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| Fanger et al. | Bispecific antibodies for targeted cellular cytotoxicity | |
| JP2021528423A5 (https=) | ||
| JP2020536109A5 (https=) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP7004761B2 (ja) | 癌治療のための改善された細胞組成物および方法 | |
| JP2019515008A5 (https=) | ||
| HRP20220014T1 (hr) | Postupci liječenja raka kože davanjem inhibitora pd-1 | |
| JP2019502676A5 (https=) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| WO2013169693A1 (en) | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody | |
| FI3810281T3 (fi) | Menetelmiä syövän hoitamiseksi bispesifisillä anti-CD3XMUC16-vasta-aineilla ja anti-PD-1-vasta-aineilla | |
| JP2015525791A5 (https=) | ||
| JP2019503387A5 (https=) | ||
| JP2009518441A5 (https=) | ||
| JP2020510039A5 (https=) | ||
| JP2025026572A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| RS63238B1 (sr) | Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom | |
| JP2022523530A5 (https=) | ||
| CN103179987A (zh) | 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物 | |
| JP2006528627A5 (https=) | ||
| JP2021517144A (ja) | Ｃｄ４７遮断療法およびｃｄ３８抗体の組み合わせ | |
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review |